Neurocrine Biosciences
NBIX
117 hedge funds and large institutions have $547M invested in Neurocrine Biosciences in 2013 Q4 according to their latest regulatory filings, with 22 funds opening new positions, 34 increasing their positions, 43 reducing their positions, and 27 closing their positions.
469% more call options, than puts
Call options by funds: $6.31M | Put options by funds: $1.11M
4% less funds holding
Funds holding: 122 → 117 (-5)
19% less first-time investments, than exits
New positions opened: 22 | Existing positions closed: 27
20% less capital invested
Capital invested by funds: $680M → $547M (-$133M)
21% less repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 43
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$20.1M |
| 2 |
Millennium Management
New York
|
+$7.47M |
| 3 |
BB
BB Biotech
Schaffhausen,
Switzerland
|
+$6.8M |
| 4 |
Franklin Resources
San Mateo,
California
|
+$4.84M |
| 5 |
Invesco
Atlanta,
Georgia
|
+$4.13M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
-$18.6M |
| 2 |
MG
Meditor Group
Hamilton,
Bermuda
|
-$11.9M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$6.84M |
| 4 |
PC
PointState Capital
New York
|
-$5.66M |
| 5 |
VM
VHCP Management
New York
|
-$5.62M |
NBIX Hedge Fund Activity: Q4 2013 in Review
117 of the 3,445 institutional investors tracked by Wall St. Rank reported a position in Neurocrine Biosciences (NBIX) for Q4 2013, worth a combined $547M — down 20% from $680M a quarter earlier.
Sellers outnumbered buyers: 27 funds closed out of NBIX and 22 opened new positions — a net loss of 5 holders — while 43 trimmed existing stakes and 34 added.
The largest buyer was OrbiMed, adding an estimated $20.1M. The largest seller was Jennison Associates, exiting entirely with an estimated $18.6M sold.
- 117 institutional investors held Neurocrine Biosciences (NBIX) as of Q4 2013, down from 122 in Q3 2013.
- Funds reported $547M of Neurocrine Biosciences stock for Q4 2013, down 20% quarter-over-quarter.
- 22 funds opened new Neurocrine Biosciences positions in Q4 2013 and 27 closed out, a net change of -5 holders.
- The largest Neurocrine Biosciences buyer in Q4 2013 was OrbiMed, an estimated $20.1M added.
- The largest Neurocrine Biosciences seller in Q4 2013 was Jennison Associates, an estimated $18.6M sold.
Based on aggregated 13F filings for Q4 2013.